Chordia Therapeutics Inc. (JP:190A) has released an update.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Chordia Therapeutics Inc. has announced that the World Health Organization has given an International Nonproprietary Name, rogocekib, to their CLK inhibitor CTX-712, which is currently undergoing Phase 1/2 clinical trials in the U.S. This development marks a significant step towards the commercialization of CTX-712, a promising cancer therapy.
For further insights into JP:190A stock, check out TipRanks’ Stock Analysis page.